iCAD’s ProFound AI Joins Nuance AI Marketplace for Diagnostic Imaging
World’s first and largest open AI Marketplace
expands access to ProFound AI for U.S. radiologists, 80 percent of whom use
Nuance’s radiology reporting system
NASHUA, NH — December 4, 2019 — iCAD, Inc. (NASDAQ: ICAD), a global
medical technology leader providing innovative cancer detection and therapy
solutions, today announced that its Breast Health Solutions suite will be available
on the Nuance® AI Marketplace. The Nuance AI Marketplace functions like an app store dedicated to
radiology; it is the first and largest portal with one-stop access to a wide range of AI diagnostic models
from within the industry’s most widely used radiology reporting platform.
This distribution agreement will provide iCAD
consolidated, at-scale access to users of Nuance PowerScribe™, the radiology
reporting system trusted by approximately 80 percent of U.S. radiologists
across more than 6,500 connected healthcare facilities.
iCAD’s Breast Health Solutions suite includes ProFound AI™ for Digital
Breast Tomosynthesis (DBT), the first artificial intelligence (AI) software for
DBT to be FDA-cleared, as well as software solutions for cancer detection in 2D
mammography and automated breast density assessment.
“Both ProFound AI and the Nuance AI Marketplace
address a critical need in the field of radiology as technology continues to
evolve and health care professionals now have access to more data than ever,”
said Michael Klein, Chairman and CEO of iCAD. “ProFound AI is a powerful tool
and the only software of its kind that is clinically proven to optimize
workflow and operational efficiencies for radiologists. Following its landmark
FDA-clearance in 2018, adoption of ProFound AI has steadily grown in leading
healthcare facilities worldwide, as more clinicians learn of the benefits it
offers. And with 8 in 10 of radiologists in the U.S. already using Nuance’s
PowerScribe, this will expand the possibilities for our leading-edge technology
to be accessible to even more clinicians.”
ProFound
AI for DBT was FDA-cleared, CE marked, and Health Canada licensed in 2018.
Trained with one of the largest available DBT datasets, the software rapidly
and accurately analyzes each DBT image, or slice, and provides radiologists
with key information, such as Certainty of Finding lesion and Case Scores,
which assists in clinical decision-making and improving reading efficiency.
Featuring the latest in deep-learning artificial intelligence, the algorithm
allows for continuously improved performance via ongoing updates.
Clinical
data from a large reader study involving ProFound AI for DBT were recently
published in Radiology: Artificial Intelligence. According to study findings,
ProFound AI for DBT improved radiologist sensitivity by 8 percent, reduced
unnecessary patient recall rates by 7.2 percent, and slashed reading time for
radiologists by 52.7 percent.1 Additionally, ProFound
AI cut reading time by up to 57.4 percent for radiologists reading cases of
women with dense breasts.2
With Nuance PowerScribe, radiologists can discover, test, and use
algorithms from within their familiar PowerScribe workflows to increase
reporting efficiency and quality and to help care teams improve patient
outcomes and healthcare costs. A built-in feedback
channel lets users share real-world results with developers for algorithm
refinement and post-market surveillance. Hospital systems benefit with simplified
purchasing and metrics showing algorithm usage, costs, and performance.
“This
feedback channel will provide iCAD with valuable insight into real-world data and
allow us to further accelerate and amplify the development of additional AI
algorithmic capabilities within breast cancer AI,” said Stacey Stevens,
President of iCAD. “This continuous data analysis provides crucial information
that can advance clinical and workflow efficiency and enhance patient care,
improving outcomes in the years ahead.”
References:
- Conant, E. et
al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial
Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial
Intelligence. 1 (4). Accessed via https://pubs.rsna.org/doi/10.1148/ryai.2019180096 - Hoffmeister, J. (2018). Artificial Intelligence for Digital
Breast Tomosynthesis – Reader Study Results. [White paper]. Accessed via https://www.icadmed.com/assets/dmm253-reader-studies-results-rev-a.pdf
About iCAD, Inc.
Headquartered
in Nashua, NH, iCAD is a global medical technology
leader providing innovative cancer detection and therapy solutions. For more
information, visit www.icadmed.com.
“Safe
Harbor” Statement under the Private Securities Litigation Reform Act of
1995
Certain
statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited, to the
Company’s ability to defend itself in litigation matters, to achieve business and
strategic objectives, the risks of uncertainty of patent protection, the impact
of supply and manufacturing constraints or difficulties, uncertainty of future
sales levels, protection of patents and other proprietary rights, the impact of
supply and manufacturing constraints or difficulties, product market
acceptance, possible technological obsolescence of products, increased
competition, litigation and/or government regulation, changes in Medicare or
other reimbursement policies, risks relating to our existing and future debt
obligations, competitive factors, the effects of a decline in the economy or
markets served by the Company; and other risks detailed in the Company’s
filings with the Securities and Exchange Commission. The words “believe,”
“demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,”
“anticipate,” “likely,” “seek,” and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue reliance
on those forward-looking statements, which speak only as of the date the
statement was made. The Company is under no obligation to provide any updates
to any information contained in this release. For additional disclosure
regarding these and other risks faced by iCAD, please see the disclosure
contained in our public filings with the Securities and Exchange Commission,
available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
Contacts:
Media
inquiries:
Jessica
Burns, iCAD
+1-201-423-4492
Investor Relations:
LifeSci
Advisors, on behalf of iCAD, Inc.
Jeremy
Feffer, +1-212-915-2568
Nuance, PowerScribe
and the Nuance logo are registered trademarks or trademarks of Nuance
Communications, Inc. or its affiliates in the United States and/or other
countries. All other trademarks referenced herein are the property of their
respective owners.